1Research scholar, Department of Chemistry, School of Engineering and Sciences, G.D. Goenka University, Sohna Road, Gurugram. Email: karmwati.chem@igu.ac.in
2*Associate professor, Department of Chemistry, School of Engineering and Sciences, G.D. Goenka University, Sohna Road, Gurugram. Email: Priyanka.sharma1@gdgu.org
This study reports the design, synthesis, structural characterization, and biological evaluation of novel piperidine–thiazole hybrid derivatives (5a–7e). A total of fifteen compounds were successfully synthesized using an efficient and reproducible method. Their structures were confirmed through spectroscopic techniques, including NMR, IR, and mass spectrometry. The synthesized molecules incorporated diverse alkyl, aryl, and sulfur-containing substituents to explore structure–activity relationships.
The antimicrobial activity of these compounds was evaluated against Gram-positive bacteria (Staphylococcus aureus), Gram-negative bacteria (Escherichia coli), and the fungal strain Candida albicans using the minimum inhibitory concentration (MIC) method. Most compounds exhibited moderate to significant antimicrobial activity, with series 7 showing the highest potency, followed by series 6 and series 5.
Among all derivatives, compound 7d demonstrated the most promising broad-spectrum activity, with low MIC values against all tested strains. Compounds 5e and 6d also showed notable antibacterial effects, indicating the positive influence of lipophilicity and sulfur substitution. Overall, Gram-positive bacteria were more susceptible than Gram-negative bacteria.
Although less potent than standard drugs, these findings highlight the potential of piperidine–thiazole hybrids as promising leads for future antimicrobial drug development.
Keywords: Piperidine derivatives, thiazole scaffolds, antimicrobial agents, structure-activity relationship.
How to cite this article: Yadav K, Sharma P. "Development of Piperidine–Thiazole Derivatives: Synthesis, Spectral Characterization, and Structure–Activity Relationship Analysis". Int J Drug Deliv Technol. 2026;16(15s): 1009-1020. DOI: 10.25258/ijddt.16.15s.112
Source of support: Nil.
Conflict of interest: None